U
Kelly CRISPR & Gene Editing Technology ETF
XDNA
NASDAQ
$11.66 -$0.06-0.51% Volume3,659 10/03/2022 4:00PM Eastern Quotes delayed
Recommendation
--
Closing Price
NAV
Total Assets
Dividend Yield
--
Turnover Ratio
--
Expense Ratio
Rating
Reward
Risk
Fund Information
Fund Type
ETF
Category
Prospectus Objective
Inception Date
Open/Closed to New Investors
Minimum Initial Investment
Minimum Subsequent Investment
Front End Fee
Back End Fee
Asset Allocation
Cash
Stock
U.S. Stock
Non U.S. Stock
Bond
U.S. Bond
Non-U.S. Bond
Preferred
Convertible
Other
Services Offered
None
Performance
Loading...
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
Last Bull Market Total Return
--
Last Bear Market Total Return
Forward Dividend Yield
Price
1-Month Low
1-Month High
52-Week Low
52-Week High
NAV
1-Month Low
1-Month High
52-Week Low
52-Week High
Beta / Standard Deviation
Beta
--
Standard Deviation
--
Company Information
Provider
Strategic
Manager/Tenure
(Years)
Anand Desai (0), Dustin Lewellyn (0), Ernesto Tong (0)
Address
Strategic Latin America Fund
803 West Michigan Street
Milwaukee WI - 53233-2301
Country
United States
Phone Number
888-716-7116
Investment Strategy
The investment seeks to track the total return performance of the Strategic CRISPR & Gene Editing Technology Index. The adviser employs a “passive management” investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies. It is non-diversified.
Weiss Ratings